Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer

Research output: Contribution to journalArticle

Abstract

Purpose: Limited information exists regarding the long-term risk of skeletal fracture in men on androgen suppression for prostate cancer. In addition, the clinical risk factors predisposing them to skeletal fracture are incompletely defined. We define the long-term risk and clinical risk factors for skeletal fracture in patients with prostate cancer on chronic androgen suppression. Materials and Methods: A total of 181 consecutive patients with prostate cancer on androgen suppression therapy were evaluated. The primary end point was skeletal fracture. Comprehensive demographic information was gathered, and univariate and multivariate analyses were performed to identify associations with skeletal fracture. Results: The proportion of patients who had survived fracture-free at 5 and 10 years on androgen suppression therapy was 96% and 80%, respectively. The black race (p=0.009) and increased body mass index (p=0.024) were identified as protective against androgen suppression associated skeletal fractures. A significant correlation was identified between the duration of androgen suppression and risk of skeletal fracture (p=0.003). Conclusions: Patients with prostate cancer treated with androgen suppression are at risk for skeletal fracture, and risk increases with the duration of therapy. Slender white men are at greatest risk. Conversely, black men and those with body mass indexes greater than normal (greater than 25 kg./m.2) are at minimal risk despite a prolonged duration (10 years) of androgen suppression.

Original languageEnglish (US)
Pages (from-to)1724-1728
Number of pages5
JournalJournal of Urology
Volume166
Issue number5
StatePublished - 2001

Fingerprint

Androgens
Osteoporosis
Prostatic Neoplasms
Incidence
Body Mass Index
Therapeutics
Multivariate Analysis
Demography

Keywords

  • Fractures
  • Prostatic neoplasms
  • Skeleton

ASJC Scopus subject areas

  • Urology

Cite this

@article{38acc90f5ef24cde8727962c377e6893,
title = "Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer",
abstract = "Purpose: Limited information exists regarding the long-term risk of skeletal fracture in men on androgen suppression for prostate cancer. In addition, the clinical risk factors predisposing them to skeletal fracture are incompletely defined. We define the long-term risk and clinical risk factors for skeletal fracture in patients with prostate cancer on chronic androgen suppression. Materials and Methods: A total of 181 consecutive patients with prostate cancer on androgen suppression therapy were evaluated. The primary end point was skeletal fracture. Comprehensive demographic information was gathered, and univariate and multivariate analyses were performed to identify associations with skeletal fracture. Results: The proportion of patients who had survived fracture-free at 5 and 10 years on androgen suppression therapy was 96{\%} and 80{\%}, respectively. The black race (p=0.009) and increased body mass index (p=0.024) were identified as protective against androgen suppression associated skeletal fractures. A significant correlation was identified between the duration of androgen suppression and risk of skeletal fracture (p=0.003). Conclusions: Patients with prostate cancer treated with androgen suppression are at risk for skeletal fracture, and risk increases with the duration of therapy. Slender white men are at greatest risk. Conversely, black men and those with body mass indexes greater than normal (greater than 25 kg./m.2) are at minimal risk despite a prolonged duration (10 years) of androgen suppression.",
keywords = "Fractures, Prostatic neoplasms, Skeleton",
author = "Epstein, {Jonathan Ira} and Patrick Walsh and Carter, {H Ballentine}",
year = "2001",
language = "English (US)",
volume = "166",
pages = "1724--1728",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Skeletal fracture associated with androgen suppression induced osteoporosis

T2 - The clinical incidence and risk factors for patients with prostate cancer

AU - Epstein, Jonathan Ira

AU - Walsh, Patrick

AU - Carter, H Ballentine

PY - 2001

Y1 - 2001

N2 - Purpose: Limited information exists regarding the long-term risk of skeletal fracture in men on androgen suppression for prostate cancer. In addition, the clinical risk factors predisposing them to skeletal fracture are incompletely defined. We define the long-term risk and clinical risk factors for skeletal fracture in patients with prostate cancer on chronic androgen suppression. Materials and Methods: A total of 181 consecutive patients with prostate cancer on androgen suppression therapy were evaluated. The primary end point was skeletal fracture. Comprehensive demographic information was gathered, and univariate and multivariate analyses were performed to identify associations with skeletal fracture. Results: The proportion of patients who had survived fracture-free at 5 and 10 years on androgen suppression therapy was 96% and 80%, respectively. The black race (p=0.009) and increased body mass index (p=0.024) were identified as protective against androgen suppression associated skeletal fractures. A significant correlation was identified between the duration of androgen suppression and risk of skeletal fracture (p=0.003). Conclusions: Patients with prostate cancer treated with androgen suppression are at risk for skeletal fracture, and risk increases with the duration of therapy. Slender white men are at greatest risk. Conversely, black men and those with body mass indexes greater than normal (greater than 25 kg./m.2) are at minimal risk despite a prolonged duration (10 years) of androgen suppression.

AB - Purpose: Limited information exists regarding the long-term risk of skeletal fracture in men on androgen suppression for prostate cancer. In addition, the clinical risk factors predisposing them to skeletal fracture are incompletely defined. We define the long-term risk and clinical risk factors for skeletal fracture in patients with prostate cancer on chronic androgen suppression. Materials and Methods: A total of 181 consecutive patients with prostate cancer on androgen suppression therapy were evaluated. The primary end point was skeletal fracture. Comprehensive demographic information was gathered, and univariate and multivariate analyses were performed to identify associations with skeletal fracture. Results: The proportion of patients who had survived fracture-free at 5 and 10 years on androgen suppression therapy was 96% and 80%, respectively. The black race (p=0.009) and increased body mass index (p=0.024) were identified as protective against androgen suppression associated skeletal fractures. A significant correlation was identified between the duration of androgen suppression and risk of skeletal fracture (p=0.003). Conclusions: Patients with prostate cancer treated with androgen suppression are at risk for skeletal fracture, and risk increases with the duration of therapy. Slender white men are at greatest risk. Conversely, black men and those with body mass indexes greater than normal (greater than 25 kg./m.2) are at minimal risk despite a prolonged duration (10 years) of androgen suppression.

KW - Fractures

KW - Prostatic neoplasms

KW - Skeleton

UR - http://www.scopus.com/inward/record.url?scp=0034796443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034796443&partnerID=8YFLogxK

M3 - Article

C2 - 11586210

AN - SCOPUS:0034796443

VL - 166

SP - 1724

EP - 1728

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -